Zepatier — Blue Cross Blue Shield of Montana
Hepatitis C virus (HCV) infection
Initial criteria
- BOTH of the following:
- 1. The requested length of therapy does NOT exceed the length of therapy noted in Table 10 (FDA labeling) for the patient’s treatment regimen AND
- 2. The requested quantity (dose) does NOT exceed the program quantity limit
Approval duration
BCBSIL: 12 months; other plans: up to duration per Table 10